NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $75.06 +1.22 (+1.65%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$75.00 -0.06 (-0.08%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ionis Pharmaceuticals Stock (NASDAQ:IONS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$73.97▼$75.6950-Day Range$69.68▼$77.6052-Week Range$32.00▼$86.74Volume2.01 million shsAverage Volume1.88 million shsMarket Capitalization$12.40 billionP/E RatioN/ADividend YieldN/APrice Target$100.90Consensus RatingModerate Buy Company Overview Ionis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders. Since its founding in 1989 by Dr. Stanley T. Crooke, Ionis has advanced more than 40 investigational drugs into clinical development, successfully bringing several treatments to market through strategic partnerships. Notably, the company collaborated with Biogen on the launch of Spinraza® (nusinersen), the first approved treatment for spinal muscular atrophy, and has licensed other products to global biopharmaceutical companies such as AstraZeneca and Roche. Ionis also established Akcea Therapeutics as a subsidiary to commercialize assets in rare diseases, reflecting its commitment to specialized patient populations. Headquartered in Carlsbad, California, Ionis operates research and development centers in the United States and maintains partnerships that enable commercial reach in North America, Europe and Asia-Pacific regions. The company employs teams of scientists, clinicians and manufacturing experts to advance RNA-modulating therapies from early discovery through late-stage clinical trials. Ionis’ integrated manufacturing capabilities support both internal programs and external collaborations, reinforcing its role as a leader in oligonucleotide production. Under the leadership of Executive Chairman Stanley T. Crooke and President & Chief Executive Officer Brett P. Monia, Ionis continues to invest in next-generation RNA platforms, including ligand-conjugated ASOs and splice-modulating compounds. The company’s strategic focus on precision medicine and its platform-derived pipeline position Ionis to address unmet medical needs and expand the application of RNA-targeted therapies worldwide.AI Generated. May Contain Errors. Read More Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 245th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 16 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialIonis Pharmaceuticals has a consensus price target of $100.90, representing about 34.4% upside from its current price of $75.06.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.76) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -36.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -36.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 25.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.13% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.04.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 18.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.94 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows3 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,406,452.00 in company stock.Percentage Held by Insiders2.60% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Stock News HeadlinesCitigroup initiates coverage of Ionis Pharmaceuticals (IONS) with buy recommendationMay 20 at 8:33 PM | msn.comIonis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlookMay 19 at 11:11 PM | msn.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 21 at 1:00 AM | Weiss Ratings (Ad)Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 10:10 AM | seekingalpha.comIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in ...May 14, 2026 | uk.finance.yahoo.comBiogen posts mid-stage trial data for Alzheimer’s candidate developed with IonisMay 14, 2026 | msn.comIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's diseaseMay 14, 2026 | businesswire.comA Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price MovesMay 14, 2026 | finance.yahoo.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $79.11 at the beginning of the year. Since then, IONS stock has decreased by 5.1% and is now trading at $75.06. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its earnings results on Wednesday, April, 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.29. The company's quarterly revenue was up 86.4% compared to the same quarter last year. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Top institutional investors of Ionis Pharmaceuticals include Pictet Asset Management Holding SA (0.87%), Arrowstreet Capital Limited Partnership (0.45%), Eversept Partners LP (0.38%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, C Frank Bennett, Brian Birchler, Eugene Schneider, Patrick R O'neil, Richard S Geary, B Lynne Parshall, Michael R Hayden, Joseph H Wender, Onaiza Cadoret-Manier, Eric Swayze, Kyle Jenne, Joseph Baroldi, Shannon L Devers, Joseph Klein III, Holly B Kordasiewicz and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings4/29/2026Today5/20/2026AGM 20266/04/2026Status update6/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/10/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IONS's financial health is in the Green zone, according to TradeSmith. IONS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees1,402Year Founded1989Price Target and Rating Average Price Target for Ionis Pharmaceuticals$100.90 High Price Target$130.00 Low Price Target$65.00 Potential Upside/Downside+34.4%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$381.39 million Net Margins-30.91% Pretax Margin-30.73% Return on Equity-58.65% Return on Assets-10.07% Debt Debt-to-Equity Ratio2.75 Current Ratio4.10 Quick Ratio4.09 Sales & Book Value Annual Sales$944 million Price / Sales13.14 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book25.27Miscellaneous Outstanding Shares165,260,000Free Float160,966,000Market Cap$12.40 billion OptionableOptionable Beta0.38 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:IONS) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
